Fig. 3. A_2AR antagonist and anti-TIM3 mAb synergistically suppress RencaHA tumor growth.

a RencaHA tumor-bearing BALB/c mice were injected i.v. twice with 5 × 10⁶ purified CL4 CTL on days 12 and 14 and treated with A_2AR-antagonist, anti-TIM3 mAb, or vehicle + isotype-control antibody, as shown. Tumor growth is displayed as mean tumor volumes + SEM with N = 42 mice over three independent experiments, with at least 11 mice per group. b The ratio of final to initial (day 12) tumor volume of tumors in a is given with the mean ± SEM (independent two-sample t-test). c R-values representing the growth rate of tumors in a, between 12 and 16 days, are given with the mean ± SEM (independent two-sample t-test). d Proportion of tumors across all experimental replicates in a which were regressed are given as bars ±SEM with proportion in individual experimental replicates as dots. Neither analysis of pooled data using Fisher’s exact Boschloo test nor of experimental replicates using 1-way ANOVA yield significant differences. e Progression free survival of mice in a is given. Cox Proportional Hazards Regression analysis. Treatment did not significantly predict progression free survival: (p = 0.24 ATT control; p = 0.40 ATT + A_2AR-Antagonist; p = 0.30 ATT + A_2AR-Antagonist + Anti-TIM3 mAb). Hazard ratio of progression versus Control was as follows: ATT + A_2AR-Antagonist = 0.36 (0.61 ± 3.38), ATT + A_2AR-Antagonist + Anti-TIM3 mAb = −0.53 (0.21 ± 1.63). Source data are provided in Supplementary Data 2.